The Zepbound vs. Wegovy Ad Fight in 2026: What the New Court Ruling Means for Patients Choosing a GLP-1

Novo Nordisk, which makes Wegovy and Ozempic, sued Eli Lilly in July 2026, arguing that Lilly's comparison ads for Zepbound and Mounjaro amounted to false advertising. Novo's core complaint: the ads stack the highest doses of Lilly's tirzepatide against lower doses of Novo's semaglutide, and they lean on a trial that tested the original Wegovy rather than the newer high-dose version (Wegovy HD, 7.2 mg) that Novo launched this year.

Novo asked Judge Zahid Quraishi of the U.S. District Court in Trenton for a preliminary injunction — an order forcing Lilly to stop running the ads while the case plays out. After a two-day hearing in August, the judge said no.

In a 25-page decision, Judge Quraishi found that Novo failed to show the ads were causing the kind of "irreparable harm" that justifies an emergency order. Wegovy prescriptions stayed stable during the April-to-July period the ads ran, Lilly's ads had at most a "negligible" market impact, and if Novo eventually proves real damage, money can compensate for it. He called Novo's case "less than persuasive" on a "very preliminary record."

Two details matter for how you read the ads. First, the judge noted that Lilly had already softened its newer commercials after a cease-and-desist letter: they now acknowledge that high-dose Wegovy exists and state that it was not tested against Zepbound. Second, he pointed out that Novo's own Ozempic ads once claimed superiority over Lilly's Trulicity without flagging a higher-dose version — a reminder that comparison advertising is an industry habit, not a one-company problem.

Just as important is what the ruling did not decide. As Novo itself emphasized, the court "did not decide the question" of whether Lilly's advertising is false and misleading. The lawsuit continues; only the request to pull the ads immediately was denied.

The 50-pounds-versus-33-pounds claim comes from SURMOUNT-5, a 72-week head-to-head trial of 751 adults with obesity, published in the New England Journal of Medicine in May 2025. Participants took the maximum dose they could tolerate: Zepbound 10 mg or 15 mg, or Wegovy 1.7 mg or 2.4 mg.

The results were not close. People on tirzepatide (Zepbound) lost an average of 20.2% of their body weight, versus 13.7% on semaglutide (Wegovy) — a 47% greater relative weight loss. Nearly two-thirds of tirzepatide patients (64.6%) lost at least 15% of their body weight, compared with 40.1% on semaglutide. Waist circumference dropped 7.2 inches versus 5.1 inches. Side effects were mostly gastrointestinal and mild to moderate in both groups, and slightly fewer tirzepatide patients dropped out because of them (6.1% vs. 8.0%).

So the headline number in the ads is real, pulled from a well-run trial. That's precisely why a judge was never likely to find the core claim fabricated.

Real numbers can still paint an incomplete picture, and a 30-second spot leaves out several things your prescriber would want you to know.

The trial tested the original Wegovy doses. Novo's high-dose Wegovy delivers semaglutide 7.2 mg — triple the old maximum — and posted stronger results in its own trials, which we broke down in our Zepbound vs. Wegovy HD comparison. No head-to-head trial of Zepbound against Wegovy HD exists yet, so nobody can honestly tell you how that matchup ends.

Averages aren't individuals. In every GLP-1 trial, some patients respond dramatically to semaglutide and modestly to tirzepatide, and vice versa. Roughly 4 in 10 Wegovy patients in SURMOUNT-5 still lost 15% or more of their body weight — life-changing results on the "losing" drug.

The best drug is the one you can stay on. Cost, insurance coverage, supply, and how your body handles side effects like nausea, vomiting, and constipation matter more over two years than a 6.5-point difference in trial averages. Both medications carry screening considerations — neither should be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, and your provider will weigh your history of pancreatitis, gallbladder disease, and other conditions before prescribing.

Treat the ad as a conversation starter, not a verdict. If maximum average weight loss is your top priority and tirzepatide is covered and available to you, SURMOUNT-5 is a legitimate reason to start there — many clinicians now do. If semaglutide fits your coverage, budget, or tolerability better, it remains a highly effective medication with the largest long-term safety record in the class. And if you're already losing steadily on either drug, the trial is not a reason to switch: switching mid-treatment often means re-titrating and riding out side effects again.

Whichever direction you lean, make the decision with a licensed provider who knows your full history — not with a courtroom scoreboard. And if nausea has been the thing holding you back on either medication, ask about anti-nausea support rather than quietly quitting.

JoeyMed's licensed providers prescribe tirzepatide — the same active ingredient as Zepbound — through the TIRZ HD program, with telehealth visits, transparent pricing, and ongoing check-ins to manage dosing and side effects. If you're weighing tirzepatide against semaglutide, or wondering whether you qualify for GLP-1 treatment at all, start with a free online visit at JoeyMed Weight Loss. A provider will review your health history and help you pick the option you can actually stick with — which, ad wars aside, is the one that works.